體外診斷與診療一體：全球市場分析（2010∼2025年） 是由出版商Visiongain在2010年06月所出版的。
這份英文市場調查報告書包含134 Pages 價格從美金2331起跳。
本報告書為2010∼2025年體外診斷市場的前景相關的定量、定性的分析，並有診療一體方案的收益預測與成長率等，概述如下。
第1章 總綱
第2章 體外診斷導論
第3章 體外診斷市場：全球市場觀察（2010∼2025年）
- 全球體外診斷（IVD）市場：2009年
- 全球IVD市場前景：2010∼2025年
- EDMA各範疇預測：2010∼2025年
- 定點照護檢査預測：2010∼2025年
- 實驗室檢査預測：2010∼2025年
第4章 體外診斷：主要國市場
- 主要國：2009年
- 國別預測：2010∼2025年
- 美國體外診斷市場預測與前景：2010∼2025年
- 日本體外診斷市場預測與前景：2010∼2025年
- 歐洲體外診斷市場預測與前景：2010∼2025年
- 中國體外診斷市場預測與前景：2010∼2025年
- 印度體外診斷市場預測與前景：2010∼2025年
- 預測期間中的各國市場佔有率
- 各地區市場
第5章 體外診斷部門以及主要企業
第6章 用於體外診斷檢査的重要治療領域
- 糖尿病
- 癌
- 感染病
- 生殖檢査
- 藥物濫用
- 心血管疾病
第7章 個別化醫療與診療一體
第8章 體外診斷部門以及商業的促進因子與阻礙因子：2010∼2025年
第9章 專門家的見解
第10章 結論
圖表
Abstract
Our new report examines the commercial prospects for in vitro diagnostics
(IVD) in the global healthcare market. Those technological solutions are
playing an important role in clinical practice and pharmaceutical R&D -
increasing safety, speeding up clinical development and facilitating
regulatory acceptance. Molecular diagnostic technologies are leading
healthcare towards the goal of personalised medicine, to the benefit of
healthcare stakeholders. Molecular diagnostic tests receive support from
pharmaceutical regulators, such as the FDA.
We believe that some of the greatest opportunities ever available for
diagnostics companies are present, with important sales, licensing and
partnership developments to occur from 2010 onwards. Pharmaceutical companies
also stand to gain, through the benefits of molecular diagnostics. We predict
increasing revenues in the years ahead. Do you want to know where the
most-promising opportunities will occur? How will companies adapt to the
opportunities and challenges? In Vitro Diagnostics and Theranostics: World
Market Analysis 2010-2025 answers those and many other questions, providing
the information that you require.
Our new report also covers theranostics, a fusion of drug therapy and
diagnostics to optimise efficacy and safety, as well as streamline drug
development. Combining a drug with a diagnostic test is also known as
companion diagnostics, integrated medicine, pharmacodiagnostics and Dx/Rx
partnering. This emerging field is generating strong interest from the
healthcare industry and regulatory bodies, with the associated market
expanding as the importance of theranostics is recognised, especially in
cancer treatment.
Detailed analysis of the in vitro diagnostics industry and market
In Vitro Diagnostics and Theranostics: World Market Analysis 2010-2025
examines that sector through a comprehensive review of information sources. We
harness both primary and secondary research. This report provides unique sales
forecasts, market share analyses, discussions of emerging technologies and
analyses of commercial drivers and restraints, including a SWOT analysis.
There are over 110 tables and figures included, as well as four interviews
with experts. The result is a comprehensive market- and industry-centred
study, with detailed analyses and informed opinion to benefit your work.
Why you should buy In Vitro Diagnostics and Theranostics: World Market Analysis 2010-2025
- This report gives you the following benefits in particular:
- You will receive a comprehensive analysis of the prospects for in-vitro
diagnostics from 2010 to 2025, with quantitative and qualitative analyses
- You will receive an overall revenue forecast for that market area from
2010 to 2025, as well as those for main subdivisions (by technology and
application), with comprehensive discussions and other supporting information
- You will discover predicted revenues, growth rates and other data for
theranostic solutions from 2010 to 2025
- You will receive forecasts for IVD sales in leading national markets (US,
Japan, Germany, France, UK, Italy, Spain, China and India) from 2010 to 2025
- You will identify emerging technologies, assessing their potential
- You will discover activities of companies in the IVD sector - both
established and emerging players - including partnerships
- You will discover the drivers, restraints, competition and opportunities
influencing the in vitro diagnostics and theranostics sectors
- You will investigate under-met needs in the IVD sector, with medical
requirements and commercial opportunities discussed
- You will receive expert views from our survey, including full interview
transcripts.
You can obtain this report today
This report is essential reading for everybody interested in the healthcare
diagnostics and biotechnology sectors. With expanding patient populations and
under-met needs worldwide - especially for better-targeted and
more-cost-effective medicines - the diagnostic and pharma industries can
benefit. Do you want to harness those technological and commercial
opportunities? You can stay ahead by ordering this report today.
Table of Contents
1. Executive Summary
- 1.1 The Scope of this Report
- 1.2 Chapter Outlines
- 1.3 Research and Analysis Methods
2. Introduction to In Vitro Diagnostics
- 2.1 What are In Vitro Diagnostic Tests?
- 2.2 Classifying IVD: EDMA Classification
- 2.2.1 Clinical Chemistry
- 2.2.2 Immunochemistry
- 2.2.3 Haematology
- 2.2.4 Microbiology
- 2.2.5 Genetic Testing
- 2.3 Classifying IVD: Disease Areas
- 2.4 Regulatory Issues
- 2.4.1 FDA Classifications
- 2.4.2 Regulation of IVD Tests
- 2.5 Types of IVD Tests
- 2.6 Personalised Medicine: Pharmacogenomics, Pharmacogenetics,
Theranostics, and Proteomics
- 2.6.1 Pharmacogenomics
- 2.6.2 Proteomics
- 2.7 Sensitivity and Specificity
3. In Vitro Diagnostics Market: Global Outlook 2010-2025
- 3.1 The Global IVD Market in 2009
- 3.2 Global IVD Market: Forecast 2010-2025
- 3.3 Global IVD Market: Forecasts by EDMA Category 2010-2025
- 3.3.1 Clinical Chemistry: Forecast 2010-2025
- 3.3.2 Immunochemistry: Forecast 2010-2025
- 3.3.3 Haematology: Forecast 2010-2025
- 3.3.4 Microbiology (Culture): Forecast 2010-2025
- 3.3.5 Immunotechnology for Infectious Diseases: Forecast 2010-2025
- 3.3.6 Genetic Testing: Forecast 2010-2025
- 3.4 Point-of-Care Testing: Forecast 2010-2025
- 3.5 Laboratory Testing: Forecast 2010-2025
4. In Vitro Diagnostics: Leading National Markets
- 4.1 Leading IVD Markets in 2009
- 4.2 Forecasts by Country 2010-2025
- 4.3 US IVD Market: Forecast and Outlook 2010-2025
- 4.4 Japanese IVD Market: Forecast and Outlook 2010-2025
- 4.5 Leading European IVD Markets: Forecasts and Outlook 2010-2025
- 4.6 Chinese IVD Market: Forecast and Outlook 2010-2025
- 4.7 Indian IVD Market: Forecast and Outlook 2010-2025
- 4.8 How National Market Shares will Change During the Forecast Period
- 4.9 Global IVD Market by Region
5. Some Leading Companies in the IVD Sector
- 5.1 IVD Manufacturers
- 5.1.1 Roche
- 5.1.2 Siemens AG
- 5.1.3 Abbott Laboratories
- 5.1.4 Beckman Coulter
- 5.1.5 Becton Dickinson
- 5.2 Laboratory Services
- 5.2.1 Quest Diagnostics
- 5.2.2 Laboratory Corporation of America
- 5.3 Direct-to-Consumer Genomic Testing Companies
6. Important Therapy Areas for IVD Tests
- 6.1 Diabetes
- 6.2 Oncology
- 6.3 Infectious Disease
- 6.3.1 Hospital-Acquired Infections
- 6.3.2 HIV
- 6.3.3 Tuberculosis
- 6.3.3.1 Skin Tests
- 6.3.3.2 Smear Microscopy
- 6.3.3.3 Microbiological Culture
- 6.3.3.4 Nucleic Acid-Based Testing
- 6.3.3.5 Immunoassays
- 6.3.3.6 Phage Assay
- 6.3.4 Influenza
- 6.4 Reproductive Tests
- 6.5 Drugs of Abuse
- 6.5.1 Drugs Commonly Tested For
- 6.5.2 Types of Sample
- 6.6 Cardiovascular Disease
- 6.6.1 Cardiac Markers
- 6.6.2 Cholesterol Screening
7. Personalised Medicine and Theranostics
- 7.1 What is Personalised Medicine?
- 7.2 Maximising Benefits to Healthcare Stakeholders
- 7.3 Minimising Harm
- 7.4 Increasing Patient Compliance
- 7.5 Streamlining Clinical Trials
- 7.6 Reviving Failed or Withdrawn Drugs
- 7.7 Reducing the Costs of Healthcare
- 7.8 Shifting From Reaction to Prevention
- 7.9 What is Required for Personalised Medicine to Become Widespread?
- 7.9.1 The Cost of Genomic Sequencing Must Fall Further
- 7.9.2 Large-Scale Studies and Databases
- 7.9.3 A Healthcare IT Infrastructure that Integrates Clinical Data and
Other Research
- 7.9.4 Medical Education
- 7.9.5 Guaranteed Reimbursements?
- 7.10 Theranostics Forecast
8. Commercial Drivers and Restraints in the IVD Sector 2010-2025
- 8.1 SWOT Analysis of the IVD Market Area
- 8.2 Factors Driving Growth of the IVD Market
- 8.3 Factors Restraining Growth of the IVD Market
9. Interviews with Industry Experts
- 9.1 Interview 1: Director of a Diagnostics Company
- 9.1.1 Most-Promising Therapeutic Areas for IVD
- 9.1.2 Unmet Medical Needs in IVD
- 9.1.3 Greatest Obstacles to Market Growth
- 9.1.4 Prospects for IVD Market Growth in Developing Countries
- 9.1.5 Prospects for Theranostics
- 9.2 Interview 2: CEO of a Diagnostics Company
- 9.2.1 Most-Promising Therapeutic Areas for IVD
- 9.2.2 Unmet Medical Needs in IVD
- 9.2.3 Greatest Obstacles to Market Growth
- 9.2.4 Prospects for IVD Market Growth in Developing Countries
- 9.2.5 Prospects for Theranostics
- 9.3 Interview 3: Director of a Diagnostics Company
- 9.3.1 Most-Promising Therapeutic Areas for IVD
- 9.3.2 Unmet Medical Needs in IVD
- 9.3.3 Greatest Obstacles to Market Growth
- 9.3.4 Prospects for IVD Market Growth in Developing Countries
- 9.3.5 Prospects for Theranostics
- 9.4 Interview 4: Business Development Director of a Diagnostics Company
- 9.4.1 Most-Promising Therapeutic Areas for IVD
- 9.4.2 Unmet Medical Needs in IVD
- 9.4.3 Greatest Obstacles to Market Growth
- 9.4.4 Prospects for IVD Market Growth in Developing Countries
- 9.4.5 Prospects for Theranostics
10. Conclusions
- 10.1 In Vitro Diagnostics are Vital to Clinical Decision Making
- 10.2 Significant Growth of In Vitro Diagnostics Market from 2010 to 2025
- 10.3 The Top Five Manufacturers Command the Majority of the IVD Market
- 10.4 Expansion of the World Market Boosted by Rising Sales in the
Developing Healthcare Markets
- 10.5 IVD Solutions are the Cornerstone of Personalised Medicine
- 10.6 Expansion into Developing National Markets and Lifestyle Diseases
Will Drive Market
List of Tables
- Table 2.1 Criticisms of the CLIA System
- Table 3.1 Global IVD Market: Revenues by EDMA Category, 2009
- Table 3.2 The Global IVD Market: Revenue Forecast, 2010-2025
- Table 3.3 Global IVD Market: Revenue Forecast by Submarket, 2010-2015
- Table 3.4 Clinical Chemistry IVD Applications, 2010
- Table 3.5 Clinical Chemistry IVD Market: Revenue Forecast, 2010-2025
- Table 3.6 Immunochemistry IVD Applications, 2010
- Table 3.7 Immunochemistry IVD Market: Revenue Forecast, 2010-2025
- Table 3.8 Haematology IVD Applications, 2010
- Table 3.9 Haematology IVD Market: Revenue Forecast, 2010-2025
- Table 3.10 Microbiological Culture Applications, 2010
- Table 3.11 Microbiology Culture IVD Market: Revenue Forecast, 2010-2025
- Table 3.12 Infectious Immunology Applications, 2010
- Table 3.13 Infectious Immunology Market: Revenue Forecast, 2010-2025
- Table 3.14 Genetic Testing Applications, 2010
- Table 3.15 Genetic Testing Market: Revenue Forecast, 2010-2025
- Table 3.16 POCT and Laboratory Testing Market Shares by Revenue, 2009
- Table 3.17 The Point-of-Care IVD Market: Revenue Forecast, 2010-2025
- Table 3.18 The Laboratory Testing Market: Revenue Forecast, 2010-2025
- Table 3.19 The Laboratory Testing and POCT Markets: Revenue Forecasts,
2010-2025
- Table 4.1 Leading IVD Markets by Revenue, 2009
- Table 4.2 Nine Leading National IVD Markets: Revenue Forecasts, 2010-2025
- Table 4.3 The US IVD Market: Revenue Forecast, 2010-2025
- Table 4.4 The US IVD Market: Revenue Forecast, 2010-2025
- Table 4.5 Healthcare Budgets and IVD Spending of Top Five European
Countries, 2009
- Table 4.6 The German IVD Market: Revenue Forecast, 2010-2025
- Table 4.7 The French IVD Market: Revenue Forecast, 2010-2025
- Table 4.8 The Italian IVD Market: Revenue Forecast, 2010-2025
- Table 4.9 The Spanish IVD Market: Revenue Forecast, 2010-2025
- Table 4.10 The UK IVD Market: Revenue Forecast, 2010-2025
- Table 4.11 The Chinese IVD Market: Revenue Forecast, 2010-2025
- Table 4.12 The Indian IVD Market: Revenue Forecast, 2010-2025
- Table 4.13 Global IVD Market by Regional Revenue Shares, 2009
- Table 5.1 Top Five IVD Manufacturers by Revenue, 2009
- Table 5.2 Roche: Diagnostic Business Revenues, 2009
- Table 5.3 Roche: Bestselling IVD Products, 2009
- Table 5.4 Siemens: Revenues by Business Segment, 2009
- Table 5.5 Abbott: Revenues by Business Segment, 2009
- Table 5.6 Beckman Coulter: Revenues by Business Segment, 2009
- Table 5.7 BD: Revenues by Business Segment, 2009
- Table 5.8 Quest: Revenues by Business Segment, 2009
- Table 5.9 LabCorp: Revenues by Business Segment, 2009
- Table 5.10 Conditions Tested for by 23andMe, 2010
- Table 6.1 Key Disease Areas: Revenues from IVDs, 2009
- Table 6.2 Diabetes Market by Marker, 2009
- Table 6.3 POCT by Application, 2009
- Table 6.4 Cancer IVD Revenues, 2009
- Table 6.5 Theranostics for Oncology, 2010
- Table 6.6 Infectious Disease IVD Market by Technology, 2009
- Table 6.7 Infectious Disease IVD Market: Revenues by Disease, 2009
- Table 6.8 HIV IVD Market: Revenues by Application, 2009
- Table 6.9 TB Diagnostics by Revenue, 2009
- Table 6.10 Male and Female Fertility Markers, 2010
- Table 6.11 Detection Windows for Various DoA Tests, 2010
- Table 6.12 Cardiovascular IVD Market: Revenue by Application, 2009
- Table 6.13 Common Cardiac Markers, 2010
- Table 6.14 Cardiac Marker IVD Market: Revenues by Test Type, 2009
- Table 7.1 Comparison of Traditional and Personalised Medicine, 2010
- Table 7.2 Average Response Rates to Treatment for Various Diseases, 2010
- Table 7.3 Drugs Metabolised by CYP450: 2C19 and 2D6, 2010
- Table 7.4 The Falling Cost of Sequencing Complete Human Genome
- Table 7.5 Diagnostics and Theranostics: Revenue Forecasts, 2010-2025
- Table 7.6 Genetic IVDs: Theranostics and Other Tests Revenue Forecasts,
2010-2025
- Table 8.1 SWOT Analysis of IVD Market, 2010-2025
List of Figures
- Figure 3.1 Global IVD Market: Revenues by EDMA Category, 2009
- Figure 3.2 The Global IVD Market: Revenue Forecast, 2010-2025
- Figure 3.3 Global IVD Market: Revenue Forecast by Submarket, 2010-2015
- Figure 3.4 Clinical Chemistry IVD Market: Revenue Forecast, 2010-2025
- Figure 3.5 Immunochemistry IVD Market: Revenue Forecast, 2010-2025
- Figure 3.6 Haematology IVD Market: Revenue Forecast, 2010-2025
- Figure 3.7 Microbiology Culture IVD Market: Revenue Forecast, 2010-2025
- Figure 3.8 Infectious Immunology Market: Revenue Forecast, 2010-2025
- Figure 3.9 Genetic Testing Market: Revenue Forecast, 2010-2025
- Figure 3.10 POCT and Laboratory Testing Market Shares, 2009
- Figure 3.11 The Point-of-Care IVD Market: Revenue Forecast, 2010-2025
- Figure 3.12 The Laboratory Testing Market: Revenue Forecast, 2010-2025
- Figure 3.13 The Laboratory Testing and POCT Markets: Revenue Forecasts,
2010-2025
- Figure 4.1 Leading National IVD Markets by Share of Worldwide Revenue, 2009
- Figure 4.2 Leading National IVD Markets (Upper Tier): Revenue Forecasts,
2010-2025
- Figure 4.3 Leading National IVD Markets (Lower Tier): Revenue Forecast,
2010-2025
- Figure 4.4 The US IVD Market: Revenue Forecast, 2010-2025
- Figure 4.5 The Japanese IVD Market: Revenue Forecast, 2010-2025
- Figure 4.6 The German IVD Market: Revenue Forecast, 2010-2025
- Figure 4.7 The French IVD Market: Revenue Forecast, 2010-2025
- Figure 4.8 The Italian IVD Market: Revenue Forecast, 2010-2025
- Figure 4.9 The Spanish IVD Market: Revenue Forecast, 2010-2025
- Figure 4.10 The UK IVD Market: Revenue Forecast, 2010-2025
- Figure 4.11 The Chinese IVD Market: Revenue Forecast, 2010-2025
- Figure 4.12 The Indian IVD Market: Revenue Forecast, 2010-2025
- Figure 4.13 Market Shares of Leading National Markets, 2010
- Figure 4.14 Market Shares of Leading National Markets, 2015
- Figure 4.15 Market Shares of Leading National Markets, 2020
- Figure 4.16 Market Shares of Leading National Markets, 2025
- Figure 4.17 Global IVD Market by Region, 2009
- Figure 5.1 Market Shares of the Top Five IVD Manufacturers, 2009
- Figure 5.2 Roche: Diagnostic Business by Revenue, 2009
- Figure 5.3 Roche: Bestselling IVD Products, 2009
- Figure 5.4 Siemens Healthcare: Revenues by Division, 2009
- Figure 5.5 Siemens AG: Revenues by Business Segment, 2009
- Figure 5.6 Abbott: Revenues by Business Segment, 2009
- Figure 5.7 Beckman Coulter: Revenues by Business Segment, 2009
- Figure 5.8 BD: Revenues by Business Segment, 2009
- Figure 5.9 Quest: Revenues by Business Segment, 2009
- Figure 5.10 LabCorp: Revenues by Business Segment, 2009
- Figure 6.1 Key Disease Areas: Revenues from IVD Applications, 2009
- Figure 6.2 Diabetes Market by Marker, 2009
- Figure 6.3 POCT Market by Application, 2009
- Figure 6.4 Cancer IVD Revenues, 2009
- Figure 6.5 Infectious Disease IVD Market: Revenues by Technology, 2009
- Figure 6.6 Infectious Disease IVD Market: Revenues by Disease, 2009
- Figure 6.7 HIV IVD Market: Market Shares by Application, 2009
- Figure 6.8 TB Diagnostics by Revenue, 2009
- Figure 6.9 Cardiovascular IVD: Market Shares by Application, 2009
- Figure 6.10 Cardiac Marker IVDs: Market Shares by Test Type, 2009
- Figure 7.1 Average Response Rates to Treatment for Various Diseases, 2010
- Figure 7.2 The Falling Cost of Sequencing the Whole Human Genome
- Figure 7.3 Theranostic IVD Market: Revenue Forecast, 2010-2025
- Figure 7.4 Global IVD Market: Theranostic and Diagnostic Market Shares,
2010-2025
- Figure 7.5 Genetic IVD Applications: Revenue Forecasts for Theranostics
and Other Tests, 2010-2025
Companies Listed
- 23andMe
- Abbott Laboratories
- AmeriPath
- Axis-Shield
- Beckman Coulter
- Becton, Dickinson & Company
- BIOTEC Laboratories
- bioTheranostics
- Cellestis
- Center for Disease Control and Prevention (CDC)
- Clinical Data
- Complete Genomics
- Dade Behring
- Dianon Systems
- Duke University
- Dynacare Laboratories
- Enterix
- EntroGen
- Esoterix
- European Diagnostic Manufacturers Association (EDMA)
- European Medicines Evaluation Agency (EMEA)
- Focus Diagnostics
- Food and Drug Administration (FDA)
- Genetics & Public Policy Center
- HemoCue
- Hologic
- Home Access Health
- Laboratory Corporation of America
- Litholink Corporation
- Modern Health Systems
- Monogram Bioscience
- Myriad Genetics
- National Genetics Institute
- National Health Service (UK NHS)
- Navigenics
- OraSure Technologies
- Oxford Immunotec
- ParagonDx
- Pathway Genomics
- Pfizer
- Prometheus
- Qiagen
- Quest Diagnostics
- Radient Pharmaceuticals
- Roche
- Siemens
- US LABS
- Vermillion Diagnostics
- ViroMed Laboratories
- Walgreens
- Warner-Chilcott
- World Health Organization (WHO)
|
